[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lower-urinary-tract-symptoms-luts-in-men-with-benign-prostatic-hyperplasia-bph\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lower-urinary-tract-symptoms-luts-in-men-with-benign-prostatic-hyperplasia-bph":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,55],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":5},"100053458","selective-median-lobe-surgery-outcomes-study-100053458",false,"NCT07699718","Selective Median Lobe Surgery Outcomes Study","UNVEIL-BPO Median Lobe Study: An International Multicenter Evaluation of Selective Median Lobe Resection and Enucleation","UNVEIL-BPO","Inclusion Criteria:\n\n* Male patients aged 45 years or older.\n\n  * Moderate-to-severe lower urinary tract symptoms due to benign prostatic obstruction or urinary retention requiring transurethral surgery.\n  * Preoperative findings suggesting median lobe-dominant or median lobe-related obstruction.\n  * Planned selective median lobe-only TURP, HoLEP, or anatomical endoscopic enucleation as part of routine clinical care.\n  * Available baseline International Prostate Symptom Score, uroflowmetry and\u002For postvoid residual volume, prostate volume, intravesical prostatic protrusion measurement, and cystoscopic assessment.\n  * Ability to provide written informed consent and comply with the follow-up schedule.\n\nExclusion Criteria:\n\n* Previous prostate surgery for benign prostatic hyperplasia.\n* Known urethral stricture requiring treatment before or during the index procedure.\n* Known neurogenic lower urinary tract dysfunction.\n* Active prostate cancer or bladder cancer requiring treatment that may confound urinary outcomes.\n* Planned complete TURP, complete HoLEP\u002FAEEP, or lateral lobe-dominant surgery.\n* Severe kissing lateral lobe obstruction considered to require complete surgery rather than selective median lobe surgery.\n* Inability to provide valid baseline or follow-up outcome data.","MALE","45 Years",{"count":20,"type":21},420,"ESTIMATED","OBSERVATIONAL","This prospective multicenter observational cohort study will evaluate clinical outcomes after selective median lobe transurethral surgery for benign prostatic obstruction. Eligible men with lower urinary tract symptoms or urinary retention who are scheduled for selective median lobe-only TURP, HoLEP, or anatomical endoscopic enucleation as part of routine clinical care will be enrolled and followed after surgery.\n\nThe study will collect preoperative clinical data, symptom scores, uroflowmetry, postvoid residual volume, prostate volume, intravesical prostatic protrusion measurements, cystoscopic anatomical findings, intraoperative variables, and postoperative outcomes. The primary outcome is composite clinical failure at 12 months.\n\nThe main aim is to identify practical preoperative urology-based anatomical and functional predictors of clinical failure after selective median lobe surgery and to develop an exploratory prediction model that may help improve patient selection in future practice.",[25,26,27,28,29],"Benign Prostatic Hyperplasia","Lower Urinary Tract Symptoms (LUTS) in Men With Benign Prostatic Hyperplasia (BPH)","Benign Prostatic Obstruction","Urinary Retention","Median Lobe Prostatic Enlargement",[31,32,33,34,35,36,37,38,39,40,41,42],"Median lobe","Intravesical prostatic protrusion","Selective median lobe surgery","Selective median lobe enucleation","Selective median lobe resection","TURP","HoLEP","Anatomical endoscopic enucleation of the prostate","Uroflowmetry","Postvoid residual","Clinical failure","Ejaculation preservation","NOT_YET_RECRUITING","2026-07-09",{"date":46,"type":47},"2026-07-13","ACTUAL",{"date":49,"type":21},"2026-09-01",{"date":51,"type":21},"2030-12-01",{"name":53,"class":54},"Necmettin Erbakan University","OTHER",{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":17,"minAge":62,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":70,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":4},"100643038","irreversible-electroporation-ire-for-the-treatment-of-lower-urinary-tract-symptoms-luts-in-men-with-benign-prostatic-hyperplasia-bph-100643038","NCT07640776","Irreversible Electroporation (IRE) for the Treatment of Lower Urinary Tract Symptoms (LUTS) in Men With Benign Prostatic Hyperplasia (BPH)","RELIEF","Inclusion Criteria:\n\n1. Male, age ≥50 years.\n2. Clinical diagnosis of symptomatic benign prostatic hyperplasia (BPH).\n3. International Prostate Symptom Score (IPSS) ≥13 at screening.\n4. Peak urinary flow rate (Qmax) ≤12 mL\u002Fsec on non-catheterized free flow with voided volume ≥125 mL.\n5. Post-void residual (PVR) ≤250 mL.\n6. Prostate volume between 30 cc and 80 cc by transrectal ultrasound (TRUS) or Magnetic Resonance Imaging (MRI).\n7. Willing and able to comply with all study procedures and follow-up requirements.\n8. Able to provide written informed consent.\n9. Life expectancy ≥10 years.\n\nExclusion Criteria:\n\n1. Patients with ≥ Grade Group 2 prostate cancer (≥ Gleason score 7).\n2. Patients with Grade Group 1 prostate cancer (Gleason score 6) on active surveillance for less than 1 year.\n3. Patients with PSA ≥10 ng\u002FmL or PSA density ≥0.15 ng\u002FmL2.\n4. Prior surgical or minimally invasive intervention for BPH (e.g., TURP, Rezūm™, UroLift®, laser therapy).\n5. Presence of urethral stricture or bladder neck contracture.\n6. Patients with a history of pelvic radiation\u002Firradiation.\n7. Patients with compromised renal function (serum creatinine level \\>1.8 mg\u002FdL or upper-tract disease).\n8. Obstructing median lobe intravesical prostatic protrusion (IPP) with \\>1 cm assessed by TRUS or MRI.\n9. Active urinary tract infection, prostatitis, or gross hematuria within 3 months of enrollment.\n10. Active need of catheterization.\n11. Known or suspected neurogenic bladder or underlying neurologic disease affecting bladder function (e.g., Parkinson's disease, multiple sclerosis, stroke with residual urinary symptoms).\n12. History of bladder cancer or other urological malignancy.\n13. Implanted electrical devices (e.g., pacemaker, defibrillator, neurostimulator) incompatible with IRE energy delivery.\n14. Uncorrected bleeding diathesis or current therapeutic anticoagulation that cannot be safely interrupted.\n15. Current use of BPH medications unless on a stable dose for ≥6 weeks (alpha-blockers, anticholinergics, beta-3 adrenergic agonists) or ≥6 months (5-alpha reductase inhibitors, phosphodiesterase type 5 inhibitors) prior to baseline, with no planned changes during study follow-up.\n16. Prior rectal or pelvic surgery that may interfere with treatment delivery or evaluation.\n17. Desire to preserve future fertility.\n18. Severe or uncontrolled comorbidities (e.g., NYHA class III\u002FIV heart failure, uncontrolled diabetes, severe pulmonary disease) that, in the opinion of the investigator, would increase study risk or confound outcomes.\n19. Participation in another clinical trial involving an investigational drug or device within 30 days prior to enrollment.\n20. Patients who are members of a vulnerable population, such as the cognitively challenged or incarcerated, that could expose them to undue influence, coercion, or inability to provide informed consent.","50 Years",{"count":64,"type":21},40,"INTERVENTIONAL",[67],"NA","This study will evaluate the safety and effectiveness of using Irreversible Electroporation (IRE) for the treatment of symptomatic benign prostatic hyperplasia (BPH).",[26],[71,72],"Lower Urinary Tract Symptoms (LUTS)","Benign Prostatic Hyperplasia (BPH)","2026-06-09",{"date":75,"type":47},"2026-06-11",{"date":77,"type":21},"2026-09",{"date":79,"type":21},"2031-06",{"name":81,"class":82},"Angiodynamics, Inc.","INDUSTRY"]